Feasibility and Preliminary Efficacy Results of the Beat AML Study
Data from the prospective genomic profiling
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1549 results
ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk Stage II Colon Cancer
3-year disease-free survival rate comparable with 3- vs 6-month treatment
FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukaemia
Efficacy was confirmed in VIALE-A and VIALE-C studies
EMA Recommends Granting a Marketing Authorisation for Lenalidomide Mylan
Lenalidomide Mylan is a generic of Revlimid, which has been authorised in the EU since 2007
EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+ Cells
Intended use is for the treatment of relapsed or refractory mantle cell lymphoma
FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma
Approval was based on KEYNOTE-204
EMA Recommends Extension of Indications for Nivolumab
New indication concerns the treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma
Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is Feasible
First evidence that patients with malignant mesothelioma have gender specific differences in PDGFRα expression
Larger NGS Gene Panel Linked to More Clinical Utility
Evaluation of the clinical utility of two different size next-generation sequencing gene panels in solid tumours showed a preference for a larger panel across all tumour types investigated
Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma
Response was found to associate with specific biomarkers and biomarker modulations following treatment
The Nobel Prize in Chemistry 2020 was Awarded “for the Development of a Method for Genome Editing”
CRISPR/Cas9 system has had a revolutionary impact on the life sciences, contributing to development of new cancer therapies
Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy for Identifying Large Deletions
MET alterations may identify candidates for targeted therapy and signal decreased immunotherapy benefit in NSCLC